Genzyme/Schering AG To Initiate Campath Phase III Trial For MS
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms agree with FDA on Phase III plan despite suspension of Phase II program following three cases of severe idiopathic thrombocytopenic purpura.
You may also be interested in...
Genzyme’s Campath MS Safety Profile Expected From FDA By July; Phase III Set For Second Half
The firm expects to re-start a Phase II trial of alemtusumab in multiple sclerosis patients that was halted in 2005.
Genzyme’s Campath MS Safety Profile Expected From FDA By July; Phase III Set For Second Half
The firm expects to re-start a Phase II trial of alemtusumab in multiple sclerosis patients that was halted in 2005.
FDA Alert Warns Of Adverse Events With Genzyme/Schering AG's Campath
The alert on idiopathic thrombocytopenia purpura comes nearly three months after the companies halted dosing in a multiple sclerosis trial of alemtuzumab due to ITP events.